Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors.

Area of Science:

• Biotechnology
• Drug Discovery
• Virology

Background:

• Inhibitor screening is crucial for drug development, particularly for emerging infectious diseases like COVID-19.
• Current methods like enzyme-linked immunosorbent assays (ELISA) are time-consuming and have limitations in dynamic range.
• The interaction between SARS-CoV-2 spike protein 1 (S1) and ACE2 receptor is a key target for therapeutic intervention.

Purpose of the Study:

• To develop a rapid and sensitive inhibitor screening tool using fluorescently and magnetically modulated biosensors (MMB).
• To evaluate the MMB assay's performance in screening small molecules and neutralizing antibodies against the SARS-CoV-2 S1-ACE2 interaction.
• To provide a faster and more effective alternative to existing inhibitor screening methods.

Main Methods:

• Development of a novel assay utilizing fluorescently and magnetically modulated biosensors (MMB).
• Application of the MMB assay to screen potential inhibitors targeting the SARS-CoV-2 S1 protein and ACE2 receptor interaction.
• Comparison of MMB assay performance (sensitivity, speed, non-specific binding) against traditional ELISA methods.

Main Results:

• The MMB-based assay demonstrated high sensitivity and minimal non-specific binding.
• The assay achieved significantly faster screening times (2 hours) compared to ELISA (7-24 hours).
• Successful screening of small molecules and neutralizing antibodies as inhibitors of the S1-ACE2 interaction was achieved.

Conclusions:

• The developed MMB assay is a rapid, sensitive, and effective tool for inhibitor screening.
• This method offers a significant improvement over conventional ELISA for drug discovery, especially for viral targets.
• The MMB assay is anticipated to accelerate the development of new therapeutic candidates, including those for COVID-19.